• 1\. Age: ≥18 years old; 2. Histologically confirmed stage IIIB or IV non-small cell lung cancer; 3. Have not previously received systemic anticancer therapy for stage IIIB or IV NSCLC; 4. HER2 insertion mutation, primary HER2 point mutation or primary HER2 amplification confirmed by genetic testing of tumor tissue or blood, pleural effusion, cerebrospinal fluid and other specimens; 5. There is at least one measurable lesion determined based on RECIST 1.1; 6. ECOG score 0-1 points; 7. Expected survival period ≥ 12 weeks; 8. Cardiac ultrasound examination showed that left ventricular ejection fraction (LVEF) ≥ 50%; 9. The patient's bone marrow function, liver and kidney function were confirmed to meet the following requirements by laboratory tests before the first administration:

‣ Neutrophil count (ANC) ≥ 1,500/mm3 (1.5×109/L);

⁃ Platelet count (PLT) ≥ 75,000/mm3 (75×109/L);

⁃ Hemoglobin (Hb) ≥ 8 g/dL (80 g/L);

⁃ Serum creatinine (SCr) ≤ 1.5 times the upper limit of normal (ULN) or creatinine clearance ≥ 60 mL/min;

⁃ Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN);

⁃ Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level ≤ 2.5 times the upper limit of normal (ULN), patients with liver metastases should be ≤ 5×ULN.

‣ 10\. The subjects voluntarily joined the study, signed the informed consent form, had good compliance, and cooperated with the follow-up.